Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

80 results about "Succinamopine" patented technology

Ability to catabolize succinamopine, succinamopine lactam, and succinopine lactam is encoded by pTi AT181, pTi EU6, and pTi T10/73, but not by any of 15 other Ti and root-inducing plasmids tested.

Nanometer chitosan ultrasonic microbubble targeting prostate cancer cells and preparation and application thereof

The invention belongs to the technical field of medical preparations, and discloses nanometer chitosan ultrasonic microbubble targeting prostate cancer cells and preparation and application thereof. A method comprises the following steps of (1) mixing chitosan, methacryloyloxyethyl trimethyl ammonium chloride and N-succinimidyl 3-maleimidopropionate, and heating to react, so as to obtain modified chitosan; adding a prostate antigen, adjusting the pH (potential of hydrogen) value of a system, and continuing to react, so as to obtain a complex; (2) stirring and mixing an inert matter with low boiling point, the complex and water, so as to obtain primary emulsion; (3) adding a dispersant and an additive into an oil-phase solvent, uniformly mixing, adding the primary emulsion, stirring at high speed, adding a crosslinking agent to cure, adding a precipitating agent to precipitate, washing, centrifuging at high speed, and drying particles, so as to obtain the ultrasonic microbubble. The nanometer chitosan ultrasonic microbubble has the advantages that the targeting property is good, the tissue penetration ability is strong, the affinity is high, and the nanometer chitosan ultrasonic microbubble is suitable for the ultrasonic developing of the prostate cancer cells.
Owner:SOUTH CHINA UNIV OF TECH

Preparation method of fluorogold nanocomposite used for cell imaging

The invention relates to the technical field of preparation of composite nanoparticles and provides a preparation method of a fluorogold nanocomposite used for cell imaging. The preparation method comprises the following steps of: synthesizing gold nanoparticles; coating a polylysine shell layer onto the surfaces of the gold nanoparticles; and modifying fluorescent dye and a targeting molecule through reaction between an amino group on the surface of the shell layer and a succinimido group. The preparation method provided by the invention has the beneficial effects that electrostatic self-assembly and an amino crosslinking method are adopted for preparation, operation is simple, and cost is low; amino acid, polylysine and polypeptide molecules are biomolecules respectively and are environment-friendly, usage of a reducing agent and a surfactant with high toxicity is avoided, and biocompatibility is good; the fluorescence intensity of dye molecules and photostability in cells are improved by utilizing surface plasma effect of the gold nanoparticles; introduction of the targeting molecule improves fluorescent imaging effect of composite on specific tumour cells; the fluorogold nanocomposite has a broad application prospect in the fields of cell imaging, disease detection, research and development of targeted medicines and the like.
Owner:UNIV OF SCI & TECH BEIJING

Wormwood extract modified PP spunbond non-woven fabric and preparation method thereof

The invention relates to a wormwood extract modified PP spunbond non-woven fabric. The modified PP spunbond non-woven fabric comprises the following effective components of, in percentage by mass, 0.1%-5% of wormwood extract. According to the preparation method, the wormwood extract and porous nano material are subjected to modification treatment, and the wormwood extract is "packaged" in porous channels of the porous material due to the fact that the nano porous material has a large specific surface area, so that components of the wormwood extract cannot be damaged when the non-woven fabric is prepared later, and the performance of the non-woven fabric is improved; soluble chitin, 2-hydroxybenzimidazole, cellulose acetate butyrate, adipic dihydrazide, N-hydroxysuccinimide and polyamine are added, so that the mechanical strength, the wear resistance and the moisture absorption of the non-woven fabric are further effectively improved; the obtained modified nano composite material is added into a fat-soluble solvent to be ground, can be dispersed uniformly, and is mixed and spun with PP slices to obtain the modified PP spunbond non-woven fabric, so that the softness, air permeabilityand water absorption of the non-woven fabric can be improved.
Owner:ZHONGKE TEXTILE RES INST QINGDAO CO LTD

Large-scale preparation technology for high-purity mesalazine enteric-coated sustained-release tablet preparations

PendingCN112675142AShortening the impact of structural changesLittle effect of structural changesOrganic active ingredientsAntipyreticImideExtended release tablets
The invention discloses a large-scale preparation technology for high-purity mesalazine enteric-coated sustained-release tablet preparations. The preparation technology includes the following steps: dissolving polyglutamic acid into water, adding an N-hydroxysuccinimide NHS solution and a 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EDC solution, and performing reaction for 4-8 h at room temperature so as to obtain an activated polyglutamic acid solution; adding a cross-linking agent and an initiator with the mass ratio being 1:(0.1-0.5) into the activated polyglutamic acid solution, performing reaction for 0.5-1 h at 0-5 DEG C after uniform mixing, then mixing the product and a water-soluble polymer solution, and performing stirring reaction for 1-3 h under 30-40 DEG C to obtain water-soluble polymer-polyglutamic acid copolymer; slowly adding mesalazine and the water-soluble polymer-polyglutamic acid copolymer into a granulating machine under stirring, then adding a thickening agent, and forming a suitable soft material through stirring; and preparing the soft material into dried granules, and obtaining the high-purity mesalazine enteric-coated sustained-release tablet preparations through tablet compressing and coating. The preparation technology is simple and suitable for commercial process.
Owner:南京森博医药研发有限公司

Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases

This invention relates to chemistry and biochemistry applied to the field of medicine and is referred to a new method of prevention and therapeutic treatment of conformational diseases (CD), in particular to amyloid origin diseases by administrating an effective amount of one or more compounds, salts, prodrugs or solvates, which are considered herein as chemical chaperonins, of Formula I,
  • Where: R1: -alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O—R4;
  • R3: —COOH, —OH, —SH, —NH2, —NH-alkyl-, —NH-dithiocarbamate-alkyl, —N-alkyl-dithiocarbamate alkaline earth metal salts.
  • R4: succinimidyl group.
  • R2: —H, -alkyl; wherein the term “alkyl” is characterized by a linear or branched aliphatic chain, hydrogen and saturated carbon atoms, comprising a methyl, ethyl, n-propyl, iso-propyl, n-butyl or iso-butyl groups. Wherein, the term “alkylenyl” refers to a divalent analog of a linear or branched alkyl group, preferably ethylenyl (—CH2CH2—) or butylenyl (—CH2CH2CH2CH2—) radicals. These compounds are neutral, lipophilic, and have low molecular weight. The present invention provides a novel method for CD prevention and therapeutic treatment, by inhibition, reduction and breakdown of prefibril, protofibril, amyloid fiber and plaque structures, all of them characterized by presenting cross-β-toxic structures (e.g. Alzheimer disease (AD), Parkinson's disease (PD), Diabetes Mellitus Type II (DM2), etc.), through the administration of the Formula I compounds, which are considered herein as chemical chaperonins, in any acceptable pharmaceutical composition of one or more compounds or salts thereof, prodrug or solvate, that are capable of inhibiting, reducing, removing, etc., the formation of these structures which cause a protein misfolding, as well as to disaggregate fibers already formed.
Owner:CENT DE NEUROCIENCIAS DE CUBA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products